Table of Contents
MAPLE GROVE, Minn.— Upsher-Smith announced Friday the launch of its newly redesigned website for Qudexy XR (topiramate) Extended-Release Capsules. The enhanced website offers support tools and educational resources for those living with migraine and seeking information about preventative treatment. The company has also introduced a new Facebook page that is a source of information and support for migraine sufferers. Qudexy XR is indicated for use in the prevention of migraine headache in adults and adolescents 12 years of age and older and is also indicated to treat certain types of seizures in patients 2 years and older. Qudexy XR is taken once-daily by mouth.
Key features of the new patient-centered website include: information about migraine disease; links to migraine resources; an opt-in patient email series; tips for preventing migraine; and patient savings on Qudexy XR.
“Managing migraines is often complex, and starting a new medication routine can be challenging,” said Rusty Field, president and chief executive officer, Upsher-Smith. “Our new website was designed with that in mind, offering patients easy access to migraine support tools, information about migraine prevention treatment options and ways eligible patients can start, stay and save on Qudexy XR.”
Enhancements to the Qudexy XR website include:
- Patient Email Series: Patients can sign up to receive helpful information about what to expect while taking Qudexy XR and other migraine-related topics.
- Migraine Support: Patients can learn about the causes, symptoms and triggers of migraine; how migraine may be diagnosed; proactive steps to reduce migraine; and links to additional migraine resources.
- Patient Savings: Patients can easily access information about Access Pathways, a dedicated savings and support team that offers co-pay assistance and administrative support to help patients Start, Stay and Save on Qudexy XR therapy. Patients can present the Platinum Pass™ savings card to their pharmacist for instant savings that last all year (365 days of therapy) and is renewable annually. Commercially insured patients pay $0per prescription regardless of coverage* and no activation is required prior to going to a preferred pharmacy.
- Authorized Generic: Topiramate Extended-Release Capsules from Upsher-Smith are the authorized generic of Qudexy XR. It’s the same medication as Qudexy XR, just with a different name. The Access Pathways Program is available for both Qudexy XR and Topiramate Extended-Release Capsules.
